Vinay Prasad to Replace Peter Marks in Genetic Medicine Review Office

Vinay Prasad will assume leadership of the office responsible for reviewing certain genetic medicines, a role previously overseen by Peter Marks. This transition introduces a new figure to a field of research that has faced challenges. Prasad, known for his vocal opposition to Marks’ policies, will now guide the office’s evaluations of specific genetic medicines. His appointment brings a different perspective to the review process within this sector of research. The field has experienced difficulty, and Prasad’s leadership adds an element of unpredictability as the office moves forward with its responsibilities.

Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

Author

Mark Chiang